Strontium ranelate--does it affect the management of postmenopausal osteoporosis?
This series of articles facilitated by the Cochrane Musculoskeletal Group (CMSG) aims to place the findings of recent Cochrane musculoskeletal reviews in a context immediately relevant to general practitioners. This article considers whether the availability of strontium ranelate affects the management of postmenopausal osteoporosis.
Menzies Research Institute, University of Tasmania. tania.winzenberg@utas.edu.au
Tania
T
Winzenberg
Sandi
S
Powell
Graeme
G
Jones
D000368:Aged; D000369:Aged, 80 and over; D015519:Bone Density; D005260:Female; D050723:Fractures, Bone / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D012307:Risk Factors; D013876:Thiophenes / Q000008:administration & dosage / Q000627:therapeutic use*
D009942:Organometallic Compounds; D013876:Thiophenes; C081587:strontium ranelate